Comparative Benchmarking
In the context of the broader market, SLXN competes directly with industry leaders such as AZTR and SNOA. With a market capitalization of $4.40M, it holds a significant position in the sector. When comparing efficiency, SLXN's gross margin of N/A stands against AZTR's N/A and SNOA's 37.94%. Such benchmarking helps identify whether Silexion Therapeutics Corp is trading at a premium or discount relative to its financial performance.
